Publikationen von Liu, Xianqiong

Wang, Haichuan, Zhang, Shanshan, Zhang, Yi, Jia, Jiaoyuan, Wang, Jingxiao, Liu, Xianqiong, Zhang, Jie, Song, Xinhua, Ribback, Silvia, Cigliano, Antonio, Evert, Matthias, Liang, Bingyong, Wu, Hong, Calvisi, Diego F., Zeng, Yong und Chen, Xin (2022) TAZ is indispensable for c-MYC-induced hepatocarcinogenesis. Journal of Hepatology 76 (1), S. 123-134. Volltext nicht vorhanden.

Wang, Haichuan , Wang, Jingxiao , Zhang, Shanshan, Jia, Jiaoyuan, Liu, Xianqiong, Zhang, Jie, Wang, Pan , Song, Xinhua, Che, Li, Liu, Ke, Ribback, Silvia, Cigliano, Antonio , Evert, Matthias, Wu, Hong, Calvisi, Diego F., Zeng, Yong und Chen, Xin (2021) Distinct and Overlapping Roles of Hippo Effectors YAP and TAZ During Human and Mouse Hepatocarcinogenesis. Cellular and Molecular Gastroenterology and Hepatology 11 (4), S. 1095-1117. Volltext nicht vorhanden.

Liu, Xianqiong, Hu, Junjie, Song, Xinhua, Utpatel, Kirsten, Evert, Matthias und Calvisi, Diego F. (2019) Combined treatment with MEK and mTOR inhibitors is effective in vitro and in vivo models of hepatocellular carcinoma. Cancers 11, S. 930.

Song, Xinhua, Liu, Xianqiong, Wang, Haichuan , Wang, Jingxiao , Qiao, Yu, Cigliano, Antonio, Utpatel, Kirsten, Ribback, Silvia, Pilo, Maria G., Serra, Marina, Gordan, John D., Che, Li, Zhang, Shanshan, Cossu, Antonio, Porcu, Alberto, Pascale, Rosa M., Dombrowski, Frank, Hu, Hongbo, Calvisi, Diego F., Evert, Matthias und Chen, Xin (2018) Combined CDK4/6 and Pan-mTOR Inhibition Is Synergistic Against Intrahepatic Cholangiocarcinoma. Clinical Cancer Research 25 (1), S. 403-413. Volltext nicht vorhanden.

Dong, Mingjie, Liu, Xianqiong, Evert, Katja, Utpatel, Kirsten, Peters, Michele, Zhang, Shanshan, Xu, Zhong, Che, Li, Cigliano, Antonio , Ribback, Silvia, Dombrowski, Frank, Cossu, Antonio, Gordan, John, Calvisi, Diego F., Evert, Matthias, Liu, Yan und Chen, Xin (2018) Efficacy of MEK inhibition in a K-Ras-driven cholangiocarcinoma preclinical model. Cell Death & Disease 9 (2). Volltext nicht vorhanden.